Microarray Patch Resources
PATH is advancing the microarray patch (MAP) delivery technology platform for high priority vaccine and essential medicine global health needs.
About PATH's work advancing microarray patch technology
For more than a decade, PATH has assessed and catalyzed microarray patch (MAP) transdermal technologies that have the potential to improve access and delivery of a broad range of vaccines and essential medicines in low-resource settings . As a disruptive technology, MAPs could have a transformative impact on health.
Microarray patches, also known as microneedle patches, consist of microscopic projections that are applied to the body like a small bandage, painlessly penetrating the skin’s outermost layer to deliver a drug or vaccine to the top layers of the skin.
MAPs have shown the potential for:
- Increased thermostability (reducing cold chain burdens and facilitating access to remote areas).
- Ease-of-use (facilitating self-administration or delivery by lesser-trained health care workers).
- Needle-free delivery (eliminating the risk of needlestick injuries typically associated with needle and syringe delivery).
- Increase coverage and reduced programmatic costs (through enabling alternative delivery scenarios such as supplemental immunization activities ).
Microarray Patch Center of Excellence
PATH’s Center of Excellence for Microarray Patch Technology is a four year initiative to mobilize efforts to accelerate the development of MAPs for critical vaccines, essential medicines, and diagnostics, and ensure that the MAP delivery technology platform can maximize its impact by meeting global public health needs.
Together with the community of MAP developers, industry, and global health stakeholders, the PATH Center of Excellence aims to forge a future for MAPs that maximizes the potential of this innovative delivery technology platform. Or connect with us directly via email at: MAPs@path.org
Highlights of our work on MAPs for drug and vaccine delivery
Assessing usability and fit of MAPs
PATH conducted a user evaluation in Ghana of placebo MAP prototypes for vaccine delivery (no projections or antigen). Feedback was gathered from health care workers and vaccine recipients for maternal immunization, and caregivers for child immunization on usability, acceptability, and programmatic fit for MAPs. The results from this study will support user-center product development so that the final product is easy to use and programmatically suitable for low-resource settings. Read the full report: Evaluation of Microarray Patches for Human Factors: Considerations and Program Feasibility.
Microarray Patch technology overview
- Microneedle patches for vaccination in developing countries. (Arya 2016) Read here.
- Potential use of microarray patches for vaccine delivery in low- and middle- income countries. (Peyraud 2019). Read here.
- Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination (Boopathy) Read here.
- Intradermal immunization by Ebola virus GP subunit vaccines using microneedle patches protects mice against lethal EBOV challenge. (Liu et al 2018). Read here.
- Feasibility of hepatitis B vaccination by microneedle patch: Cellular and humoral immunity studies in rhesus macaques. (Choi, 2019). Read here.
- Skin immunization with third-generation hepatitis B surface antigen using microneedles. (Nguyen, 2019). Read here.
HIV and HIV PrEP
- Acceptability of Microarray Patches for Delivery of HIV Pre-exposure Prophylaxis (PrEP) Among Women and Health Care Providers in South Africa. (PATH 2016). Read here.
- Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension. (Mc Crudden 2018). Read here.
- Vaginal Applicator Development for Delivery of Microarray Patches Containing Rilpivirine for HIV Pre-exposure Prophylaxis. (PATH 2016). Read here
- Immune response and reactogenicity of an unadjuvanted intradermally delivered human papillomavirus vaccine using a first generation Nanopatch™ in rhesus macaques: An exploratory, pre-clinical feasibility assessment. (Meyer 2019). Read here.
- An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine. (Lee et al 2015). Read here
- Clinical study and stability assessment of a novel transcutaneous influenza vaccination using a dissolving microneedle patch.(Hirobe et al 2015). Read here.
- Opportunities and challenges in delivering influenza vaccine by microneedle patch. (Jacoby et al 2015). Read here.
- Safety, tolerability, acceptability and immunogenicity of an influenza vaccine delivered to human skin by a novel high-density microprojection array patch (Nanopatch™). (Fernando et al 2018). Read here.
- The Safety, Immunogenicity and Acceptability of Inactivated Influenza Vaccine Delivered by Microneedle Patch: a Randomized, Partially Blind, Placebo-Controlled Phase 1 Trial. (Rouphael et al 2017). Read here
- Assessing the Technical and Programmatic Feasibility of a Microarray Patch for Intradermal Delivery of Primaquine to Treat P. vivax. (PATH 2017). Read here.
Neonatal and infant health
- Transdermal delivery of gentamicin using dissolving microneedle arrays for potential neonatal sepsis. (González-Vázquez et al 2017). Read here.
- High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses. (Muller et al 2017). Read here.
- Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. (Edens et al 2015).Read here.
- Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies. (Donadei, 2019). Read here.
Usability and end-user studies
- End-user acceptability study of the nanopatchTM; a microarray patch (MAP) for child immunization in low and middle-income countries. (Guillermet et al 2019). Read here.
PATH co-chairs the Delivery Technologies Working Group within WHO’s Immunization Practices Advisory Committee (IPAC). Its mission is to maximize impact of immunization products for public-sector use, including combination vaccine/device products such as MAPs and other alternative delivery technologies. A list of resources related to vaccine delivery technologies, as well as materials developed by the Delivery Technologies Working Group, are available through TechNet-21, a global network of immunization professionals.